| abstract |
This invention relates to a group of synephrine derivatives represented by the structural formula (I), a stereoisomer thereof, a solvate thereof, or a salt thereof, for use in the treatment of cancer, possessing unexpected desirable pharmaceutical properties, in particular for the use in cancer therapy or tumor treatment, especially for glucocorticoid-resistant treatment. |